FOURKITES
29.5.2024 09:01:25 CEST | Business Wire | Press release
Leading real-time supply chain visibility provider FourKites® today announced its role as a Collaborator in the Scheduling Standards Consortium (SSC) as the first real-time visibility platform participating. FourKites joins organisations involved with the SSC — including Arrive Logistics, BlueYonder, Coyote Logistics, DHL, e2open, Echo, J.B. Hunt Transport, Lineage, Mastery, One Network Enterprises, Oracle, Ryder, TI NTG, Uber Freight, Werner and Worldwide Express — which aims to foster greater efficiency within the supply chain technology landscape.
Freight scheduling has been a pervasive problem for the supply chain, compounded by the past decade’s tremendous growth and diversification in scheduling solutions. Shippers and carriers today are responsible for juggling dozens of methods of scheduling freight with shippers, each with their own interface and API, which creates friction and inefficiencies throughout the supply chain.
In response to this challenge, J.B. Hunt and Uber Freight joined forces in 2022 to establish the SSC, to create the first universal appointment scheduling standard in the form of an API. With many leading organisations now involved and driving the Standard forward, the SSC’s goal is to simplify the integration of systems across the fragmented ecosystem between shippers, carriers and intermediaries to create a more efficient appointment scheduling process. The SSC has endorsed a universal standard for the API, released October 2, 2023, which eliminates the need for multiple interfaces and allows carriers to interact through a single interface.
“Embracing a universal scheduling API unlocks seamless coordination across supply chains,” explains Viral Parekh, Head of Logistics Operations at The Kraft Heinz Company. “As more companies endorse this unified approach, we pave the way for unparalleled system efficiency, streamlining operations and driving transformative growth throughout the industry.”
FourKites is collaborating with the SSC because of its proven commitment to optimising ecosystem performance, carrier success and building a more user-friendly operating environment. In addition, FourKites’ robust customer base and recognised industry leadership enables it to play a role in developing the API and accelerating adoption across its customer and partner network. With over 100,000 appointments scheduled in the platform every month, Slot Manager is one of FourKites’ fastest-growing products, as it significantly eliminates the friction associated with manual time slot booking.
“We’re thrilled to participate in this consortium of industry heavy-hitters,” said Mathew Elenjickal, founder and CEO of FourKites. “A single API between our Slot Manager solution and our shippers’ carrier networks will create a frictionless operating environment for everyone involved, and will make FourKites customers Shippers of Choice, with lower cost to serve and a reliable, reputable integration.”
The SSC’s main objectives are to define the API standard for sharing scheduling information, eliminate manual processes by automating interactions where possible, implement standardised interfaces and integrations across core platforms, and advocate the standard across the industry.
About the Scheduling Standards Consortium (SSC)
Founded in 2022 by Convoy, J.B. Hunt and Uber Freight, the Scheduling Standards Consortium (SSC) was established to create freight appointment scheduling standards that provide consistent visibility into the supply chain. Together with shippers, carriers and intermediaries, the SSC aims to simplify the integration of systems across the fragmented ecosystem and generate efficiency across the freight industry. To learn more, visit www.FreightAPIs.org.
About FourKites
Leading global supply chain visibility platform FourKites® empowers business leaders with comprehensive visibility into transportation, yards, warehouses, stores and beyond. Tracking more than 3.2 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,500 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529642423/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
